{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:56:28Z","timestamp":1789563388843,"version":"build-2803163510"},"reference-count":45,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO Oncol Adv"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Most patients with metastatic colorectal cancer (CRC) have microsatellite stable or mismatch repair-proficient tumors, which are resistant to immunotherapy especially in cases of liver metastases. We sought to determine whether tumor-targeted interleukin-12 (PDS01ADC) can improve outcomes for patients with CRC liver metastases managed with hepatic artery infusion pump (HAIP) chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT05286814\">NCT05286814<\/jats:ext-link>\n                      is a phase II nonrandomized trial evaluating subcutaneous PDS01ADC in combination with HAIP floxuridine and systemic chemotherapy (leucovorin, 5-fluorouracil, and oxaliplatin or leucovorin, 5-fluorouracil, and irinotecan) in patients with unresectable microsatellite stable or mismatch repair-proficient colorectal liver metastases previously treated with at least one line of systemic chemotherapy. The primary end points for the planned interim analysis were overall response rate and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Nine patients were included in this planned interim analysis. Seventy-eight percent (7\/9) of patients receiving PDS01ADC with HAIP therapy had partial or complete responses at 6 months. The median hepatic progression-free survival for patients receiving PDS01ADC + HAIP therapy was 12.7 months with a minimum follow-up of 13.1 months. Grade \u22653 toxicities occurred in 78% but were manageable and did not limit HAIP therapy. No patients developed a biliary stricture within 6 months of initiating treatment. Clinical responders to PDS01ADC demonstrated enhanced peripheral immune activation, including elevated levels of circulating T-cell subsets with stem-like features, and increased CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell:T regulatory cell ratio in tissue biopsies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Addition of PDS01ADC is not detrimental to HAIP therapy and is associated with both systemic and intratumoral immune modulation. Initial results warrant continuation to full enrollment for further evaluation of clinical and scientific end points.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/oa-25-00173","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T19:59:15Z","timestamp":1773172755000},"source":"Crossref","is-referenced-by-count":1,"title":["Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial"],"prefix":"10.1200","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8354-0881","authenticated-orcid":true,"given":"Alyssa V.","family":"Eade","sequence":"first","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0314-2875","authenticated-orcid":true,"given":"Emily C.","family":"Smith","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-2744","authenticated-orcid":true,"given":"Cecilia","family":"Monge","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen E.","family":"Hannah","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-3360","authenticated-orcid":true,"given":"Nebojsa","family":"Skorupan","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5759-3728","authenticated-orcid":true,"given":"Donna M.","family":"Hrones","sequence":"additional","affiliation":[{"name":"Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8766-8946","authenticated-orcid":true,"given":"Carolina","family":"Celades","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6661-3190","authenticated-orcid":true,"given":"Meghali","family":"Goswami","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Bagheri","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley J.","family":"Rainey","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay R.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4773-2632","authenticated-orcid":true,"given":"Carolina","family":"Larrain","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7880-2183","authenticated-orcid":true,"given":"Tracey","family":"Pu","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surajit","family":"Sinha","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka P.","family":"Desai","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0668-4164","authenticated-orcid":true,"given":"Kirsten","family":"Remmert","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audra A.","family":"Satterwhite","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-7318-841X","authenticated-orcid":true,"given":"Stacy R.","family":"Joyce","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8670-8347","authenticated-orcid":true,"given":"Aaron J.","family":"Dinerman","sequence":"additional","affiliation":[{"name":"Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradford J.","family":"Wood","sequence":"additional","affiliation":[{"name":"Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Kassin","sequence":"additional","affiliation":[{"name":"Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ifechi N.","family":"Ukeh","sequence":"additional","affiliation":[{"name":"Center for Interventional Oncology, Radiology and Imaging Sciences, Clinical Center, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5013-3851","authenticated-orcid":true,"given":"Andrew M.","family":"Blakely","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6334-6936","authenticated-orcid":true,"given":"Jeremy L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3442-4453","authenticated-orcid":true,"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiem","family":"Lassoued","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2392-8122","authenticated-orcid":true,"given":"Sofia R.","family":"Gameiro","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee N.","family":"Donahue","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":true,"given":"James L.","family":"Gulley","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7529-0557","authenticated-orcid":true,"given":"Jonathan M.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_13_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_13_3_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.ade7114"},{"key":"e_1_3_13_4_2","volume-title":"An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute","author":"SEER*Explorer","year":"2025","unstructured":"SEER*Explorer: An interactive website for SEER cancer statistics. Surveillance Research Program, National Cancer Institute, 2025. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/. Data source(s): SEER Incidence Data, November 2024 Submission (1975-2022), SEER 21 registries (excluding Illinois). Expected Survival Life Tables by Socio-Economic Standards"},{"key":"e_1_3_13_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae013"},{"key":"e_1_3_13_6_2","first-page":"682","article-title":"Impact of IL-12 in cancer","volume":"17","author":"Lu X","year":"2017","unstructured":"Lu X: Impact of IL-12 in cancer. Curr Cancer Drug Targets 17:682-697, 2017","journal-title":"Curr Cancer Drug Targets"},{"key":"e_1_3_13_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0776"},{"key":"e_1_3_13_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1947"},{"key":"e_1_3_13_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800051031"},{"key":"e_1_3_13_10_2","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins MB","year":"1997","unstructured":"Atkins MB, Robertson MJ, Gordon M, et al: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 3:409-417, 1997","journal-title":"Clin Cancer Res"},{"key":"e_1_3_13_11_2","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard JP","year":"1997","unstructured":"Leonard JP, Sherman ML, Fisher GL, et al: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541-2548, 1997","journal-title":"Blood"},{"key":"e_1_3_13_12_2","first-page":"5842","article-title":"A novel method for the detection of necrotic lesions in human cancers","volume":"48","author":"Epstein AL","year":"1988","unstructured":"Epstein AL, Chen FM, Taylor CR: A novel method for the detection of necrotic lesions in human cancers. Cancer Res 48:5842-5848, 1988","journal-title":"Cancer Res"},{"key":"e_1_3_13_13_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/ITT.S306150","article-title":"NHS-IL12, a tumor-targeting immunocytokine","volume":"10","author":"Greiner JW","year":"2021","unstructured":"Greiner JW, Morillon YM 2nd, Schlom J: NHS-IL12, a tumor-targeting immunocytokine. Immunotargets Ther 10:155-169, 2021","journal-title":"Immunotargets Ther"},{"key":"e_1_3_13_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1512"},{"key":"e_1_3_13_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.4_suppl.116"},{"key":"e_1_3_13_16_2","first-page":"969","article-title":"The blood supply of neoplasms in the liver","volume":"30","author":"Breedis C","year":"1954","unstructured":"Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 30:969-977, 1954","journal-title":"Am J Pathol"},{"key":"e_1_3_13_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2014.09.005"},{"key":"e_1_3_13_18_2","first-page":"3784","article-title":"A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil","volume":"38","author":"Ensminger WD","year":"1978","unstructured":"Ensminger WD, Rosowsky A, Raso V, et al: A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 38:3784-3792, 1978","journal-title":"Cancer Res"},{"key":"e_1_3_13_19_2","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.3390\/ijms21165876","article-title":"Anticancer strategy targeting cell death regulators: Switching the mechanism of anticancer floxuridine-induced cell death from necrosis to apoptosis","volume":"21","author":"Sato A","year":"2020","unstructured":"Sato A, Hiramoto A, Kim HS, et al: Anticancer strategy targeting cell death regulators: Switching the mechanism of anticancer floxuridine-induced cell death from necrosis to apoptosis. Int J Mol Sci 21:5876, 2020","journal-title":"Int J Mol Sci"},{"key":"e_1_3_13_20_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1853"},{"key":"e_1_3_13_21_2","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1038\/s41467-021-25393-x","article-title":"Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape","volume":"12","author":"Hicks KC","year":"2021","unstructured":"Hicks KC, Chariou PL, Ozawa Y, et al: Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape. Nat Commun 12:5151, 2021","journal-title":"Nat Commun"},{"key":"e_1_3_13_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1863-0"},{"key":"e_1_3_13_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03459-7"},{"key":"e_1_3_13_24_2","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.21037\/jgo-24-71","article-title":"Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: A phase II trial protocol","volume":"15","author":"Victory JH","year":"2024","unstructured":"Victory JH, Smith EC, Ryan CE, et al: Hepatic artery infusion pump (HAIP) therapy in combination with targeted delivery of IL-12 for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma: A phase II trial protocol. J Gastrointest Oncol 15:1348-1354, 2024","journal-title":"J Gastrointest Oncol"},{"key":"e_1_3_13_25_2","volume-title":"bioRENDER","author":"Eade A","year":"2026","unstructured":"Eade A, Smith E: bioRENDER. 2026. https:\/\/BioRender.com\/yan8n8q; https:\/\/BioRender.com\/fy7qelc"},{"key":"e_1_3_13_26_2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1182\/bloodadvances.2018016279","article-title":"TCF1 expression marks self-renewing human CD8(+) T cells","volume":"2","author":"Kratchmarov R","year":"2018","unstructured":"Kratchmarov R, Magun AM, Reiner SL: TCF1 expression marks self-renewing human CD8(+) T cells. Blood Adv 2:1685-1690, 2018","journal-title":"Blood Adv"},{"key":"e_1_3_13_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.5977"},{"key":"e_1_3_13_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000000614"},{"key":"e_1_3_13_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30862-9"},{"key":"e_1_3_13_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.24399"},{"key":"e_1_3_13_31_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-08972-y"},{"key":"e_1_3_13_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26270"},{"key":"e_1_3_13_33_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/oncolo\/oyac244","article-title":"A phase I single-arm study of biweekly NHS-IL12 in patients with metastatic solid tumors","volume":"28","author":"Gatti-Mays ME","year":"2023","unstructured":"Gatti-Mays ME, Tschernia NP, Strauss J, et al: A phase I single-arm study of biweekly NHS-IL12 in patients with metastatic solid tumors. Oncologist 28:364-e217, 2023","journal-title":"Oncologist"},{"key":"e_1_3_13_34_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaoncol.2024.6998","article-title":"Novel combination immunotherapy and clinical activity in patients with HPV-associated cancers: A nonrandomized clinical trial","volume":"11","author":"Floudas CS","year":"2025","unstructured":"Floudas CS, Goswami M, Donahue RN, et al: Novel combination immunotherapy and clinical activity in patients with HPV-associated cancers: A nonrandomized clinical trial. JAMA Oncol 11:394-399, 2025","journal-title":"JAMA Oncol"},{"key":"e_1_3_13_35_2","doi-asserted-by":"crossref","first-page":"e004561","DOI":"10.1136\/jitc-2022-004561","article-title":"Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies","volume":"10","author":"Minnar CM","year":"2022","unstructured":"Minnar CM, Chariou PL, Horn LA, et al: Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1\/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies. J Immunother Cancer 10:e004561, 2022","journal-title":"J Immunother Cancer"},{"key":"e_1_3_13_36_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2006.21.5"},{"key":"e_1_3_13_37_2","doi-asserted-by":"crossref","first-page":"20558","DOI":"10.18632\/oncotarget.16137","article-title":"Enhanced antitumor effects by combining an IL-12\/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody","volume":"8","author":"Fallon JK","year":"2017","unstructured":"Fallon JK, Vandeveer AJ, Schlom J, et al: Enhanced antitumor effects by combining an IL-12\/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody. Oncotarget 8:20558-20571, 2017","journal-title":"Oncotarget"},{"key":"e_1_3_13_38_2","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-17-0483","article-title":"Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models","volume":"23","author":"Xu C","year":"2017","unstructured":"Xu C, Zhang Y, Rolfe PA, et al: Combination therapy with NHS-muIL12 and avelumab (anti-PD-L1) enhances antitumor efficacy in preclinical cancer models. Clin Cancer Res 23:5869-5880, 2017","journal-title":"Clin Cancer Res"},{"key":"e_1_3_13_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011074"},{"key":"e_1_3_13_40_2","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1158\/1078-0432.CCR-25-1490","article-title":"Increased peripheral T stem cell-like memory features in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapy","volume":"31","author":"Goswami M","year":"2025","unstructured":"Goswami M, Celades C, Minnar CM, et al. Increased peripheral T stem cell-like memory features in patients with advanced solid tumors treated with tumor-targeting IL-12 immunocytokine therapy. Clin Cancer Res 31:4159-4173, 2025","journal-title":"Clin Cancer Res"},{"key":"e_1_3_13_41_2","doi-asserted-by":"crossref","first-page":"1321318","DOI":"10.3389\/fonc.2023.1321318","article-title":"Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine","volume":"13","author":"Minnar CM","year":"2023","unstructured":"Minnar CM, Lui G, Gulley JL, et al: Preclinical and clinical studies of a tumor targeting IL-12 immunocytokine. Front Oncol 13:1321318, 2023","journal-title":"Front Oncol"},{"key":"e_1_3_13_42_2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller BC","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, et al: Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol 20:326-336, 2019","journal-title":"Nat Immunol"},{"key":"e_1_3_13_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.12.021"},{"key":"e_1_3_13_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0524"},{"key":"e_1_3_13_45_2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.ccell.2023.08.001","article-title":"Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy","volume":"41","author":"Escobar G","year":"2023","unstructured":"Escobar G, Tooley K, Oliveras JP, et al: Tumor immunogenicity dictates reliance on TCF1 in CD8(+) T cells for response to immunotherapy. Cancer Cell 41:1662-1679 e7, 2023","journal-title":"Cancer Cell"},{"key":"e_1_3_13_46_2","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1158\/2159-8290.CD-24-1055","article-title":"Expression of IMPACT curtails metabolic plasticity and augments NK cell killing to abrogate metastatic growth","volume":"15","author":"Sinha S","year":"2025","unstructured":"Sinha S, Panda AK, Xavier das Neves R, et al. Expression of IMPACT curtails metabolic plasticity and augments NK cell killing to abrogate metastatic growth. Cancer Discov 15:2344-2373, 2025","journal-title":"Cancer Discov"}],"container-title":["JCO Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/OA-25-00173","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:20:49Z","timestamp":1775143249000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/OA-25-00173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1200\/OA-25-00173"],"URL":"https:\/\/doi.org\/10.1200\/oa-25-00173","relation":{},"ISSN":["2994-9750"],"issn-type":[{"value":"2994-9750","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"article-number":"e2500173"}}